Pull incentives for antibiotics: Duke-Margolis PAVE policy paper and PBS Newshour segments

Dear All: 

We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this!

Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to the voices calling for new economic models for antibiotics.

First, the Duke-Margolis Center for Health Policy has released both a White Paper and a viewpoint paper in JAMA describing the elements of a Priority Antimicrobial Value and Entry (PAVE) Award proposal that could be a path for the diverse and complex US market to create such a model. PAVE combines a market entry reward with population-based payments from public and private payers that phase in over time.

Second, PBS Newshour is doing a Stopping Superbugs series in which their science and economic correspondents have collaborated to tell this story. The first three episodes are out:

2 Aug 2017: We are running out of effective antibiotics
3 Aug 2017: The financial barrier
4 Aug 2017: Is there an economic cure for the problem?

We have yet to turn any of this into concrete action, but steadily expanding the conversational echo chamber is a necessary prelude to such action. I’m looking forward to the rest of the PBS broadcasts, and then next up, I think, will be the output from DRIVE-AB in early September. Stay tuned!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog.html

Upcoming meetings of interest to the AMR community:

Share

Lifeline, the Musical Story of Penicillin: A Review

Dear All, Last week I went to New York City to see one of the opening performances of Lifeline, The Musical, the world’s first musical telling the story of penicillin, Sir Alexander Fleming, and the rise of antibiotic resistance! This was my first time seeing the production in its entirety and it did not disappoint. The timing

WHO: AMR Policy Brief and Preclinical pipeline data call

Dear All, Supplementing and augmenting their review of the clinical and preclinical pipeline through 31 Dec 2023 (see the 15 June 2024 newsletter for details), WHO have now released: A call for data on preclinical antibacterial projects Scope: Traditional and non-traditional antibacterial candidates covering the WHO bacterial priority pathogens as well as other resistant pathogens of public health

UK Subscription model goes live! Value bands cover entire UK!

Dear All (with thanks to Kevin for leading on this newsletter and with a wonkish / long-read alert on this email … settle in for the ride!), Great news from TEAM UK! As of 12 August, the UK Subscription Program is no longer a pilot but is fully operational with an initial application deadline of

Needles and haystacks: Preclinical antibacterial pipeline review

Dear All, Just published in AAC is WHO’s updated review of the global preclinical pipeline. Here are the links you need to follow today’s discussion: The new WHO review: Gigante et al. “Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps”, https://doi.org/10.1128/aac.00535-24, AAC 2024. An excellent AAC podcast (overview webpage; YouTube video) discussing the WHO review. In

Scroll to Top